Annual report pursuant to Section 13 and 15(d)

COVID-19 Related Liabilities (Details)

v3.22.4
COVID-19 Related Liabilities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]      
Beginning Balance $ 22 [1] $ 26 $ 7
COVID-19 related costs 2 4 88
Cash payments (8) (6) (20)
Other 2 (3) 0
Ending Balance 26 [1] 22 [1] 26
COVID-19 Plan [Member]      
Restructuring Cost and Reserve [Line Items]      
Beginning Balance 1 6 0
COVID-19 related costs 2 1 71
Cash payments (3) (6) (64)
Other 0 0 (1) [2]
Ending Balance 0 1 6
Personnel-related      
Restructuring Cost and Reserve [Line Items]      
Beginning Balance 0 1 7
Cash payments (4) (1) (9)
Other 3 [3] 0 0
Ending Balance 6 0 1
Personnel-related | COVID-19 Plan [Member]      
Restructuring Cost and Reserve [Line Items]      
Beginning Balance 1 6 0
COVID-19 related costs 2 1 71
Cash payments (3) (6) (64)
Other 0 0 (1) [2]
Ending Balance $ 0 $ 1 $ 6
[1] See Note 26—Restructuring for details.
[2] Includes employee-related write-offs.
[3] Represents $3 million of accelerated stock-based compensation expense included in Additional paid-in capital on the Consolidated Balance Sheets.